GKL-006

Phase 2Biologic

BBeijing Gene Key Life Technology Co., Ltd

GKL-006 is one of 13 biologic programs targeting Hepatocellular Carcinoma (HCC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular Carcinoma (HCC)Recruiting

Hepatocellular Carcinoma (HCC)Phase 2

Recruiting

Competition

Competitive Landscape

17 competitors in Hepatocellular Carcinoma (HCC)

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 2

4 2

Yervoy

Bristol-Myers Squibb

Phase 2

3 3

Opdivo

Bristol-Myers Squibb

Phase 2

2 4

Beyfortus

BeiGene

Phase 2

2 5

Tecentriq

Roche

Phase 2

2 6

Farxiga

AstraZeneca

Phase 2

1 7

Zofran

Novartis

Phase 2

1 8

Actemra

Roche

Phase 2

1 9

Navmi

SSummit Therapeutics

Phase 2

1 10

Nitrostat

VViatris Specialty LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Hepatocellular Carcinoma (HCC)

NCT07209813

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma (HCC)1 trial

A Multicenter, Randomized, Open-Label, Controlled Phase 2 Study of GKL-006 Injection in Combination With Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

Recruiting·BBeijing Gene Key Life Technology Co., Ltd·Phase 2·NCT07209813·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GKL-006. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GKL-006 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GKL-006. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Gene Key Life Technology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: BBeijing Gene Key Life Technology Co., Ltd

GKL-006

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hepatocellular Carcinoma (HCC)1 trial

References

Drug Info

Quick Facts

Related News